Lonza to Expand Mammalian-Manufacturing Facilities in Switzerland, US
By Giulia Petroni
Lonza Group AG said Thursday that it will invest around 850
million Swiss francs ($930.2 million) to expand its mammalian
drug-substance manufacturing facilities in Switzerland and the
The Swiss life-sciences company said it will develop a new
large-scale facility in Visp, Switzerland, to be completed in 2024,
to meet increasing market demand for biologics.
A second small-scale, single-use technology facility will be
developed in Portsmouth, N.H., to support customers scaling
clinical to commercial manufacturing. The facility is expected to
be completed in 2023.
According to Lonza, more than 300 new jobs will be created in
Visp and 250 new positions will be recruited in Portsmouth.
Write to Giulia Petroni at firstname.lastname@example.org
(END) Dow Jones Newswires
May 06, 2021 03:12 ET (07:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.